Cytokinetics CEO Robert Blum confirmed the biotechnology company held sale talks late last year, as was reported around then by The Wall Street Journal and Reuters. In comments at a conference hosted by the investment bank Jefferies Wednesday, he said Cytokinetics engaged in “good faith negotiations” with an unnamed third party regarding an acquisition. While Cytokinetics’ board was supportive of proceeding with discussions on “substantially the terms the counterparty communicated,” that company ultimately did not move forward with an acquisition.
https://finance.yahoo.com/m/3f4be246-9c45-3f4c-b612-d9946db19f8d/lilly-details-mash-data-for.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.